Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cytomedix (OTC BB:CYDXE.OB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Chart | News | Profile
Recent Events
Aug 31Price hit new 52-week low ($0.10)
Location
Three Parkway North
Deerfield, IL 60015
Phone: (847) 405-7800
Fax: (847) 405-7801
Employees (last reported count): 55
Financial Links
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Related Links
 ·Search Yahoo! for related links...
Ownership
·Insider and 5%+ Owners: 70%
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cytomedix Inc. develops, produces, licenses and distributes cellular therapies for the treatment of wounds. At present, the Company offers two growth factor therapies for the treatment of chronic, non-healing wounds: Procuren and the AuTolo-Gel process. Both therapies are centered on harvesting and activating a patient's own platelets to isolate and release the growth factors contained in the platelets. The Procuren product and platelet gel made using the AuTolo-Gel process are designed to stimulate and accelerate a normal wound healing response in much the same way a healthy body naturally initiates healing.
More from Market Guide: Expanded Business Description

Financial Summary
CYDXE is engage in the development, sale and marketing of a proprietary system, known as the AuTolo-Cure (TM) System, for the treatment of chronic, non-healing wounds. For the three months ended 3/31/01, revenues totaled $1.2 million, up from $35 thousand. Net loss applicable to Common rose 3% to $6.7 million. Revenues benefited from sales to Curative Health Services. Higher loss reflects the issuance of warrants to acquire Cytomedix stock and warrants issued to 3rd party consultants.
More from Market Guide: Significant Developments

Officers

Position
James CourPres, CEO, Director
Glenn CharlesworthVP-Fin., CFO
David DemarestVP, Sec., Gen. Counsel
Kent SmithVP of Sales and Marketing
Robin GellerVP of Science and Technology
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- OTC BB:CYDXE.OBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 31-Aug-2001
$0.10 
Recent Price$0.10 
52-Week High
on 19-Sep-2000
$11.375
Daily Volume (3-month avg)87.2K
Daily Volume (10-day avg)7,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-98.7%
52-Week Change
relative to S&P500
-98.3%
Share-Related Items
Market Capitalization$1.07M
Shares Outstanding10.7M
Float3.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)-$0.04 
Earnings (ttm)-$3.17 
Earnings (mrq)-$0.63 
Sales (ttm)$0.14 
Cash (mrq)$0.05 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)0.70 
Income Statements
Sales (ttm)$1.50M
EBITDA (ttm)-$24.8M
Income available to common (ttm)-$33.5M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter31-Mar-2001
Management Effectiveness
Return on Assets (ttm)-512.17%
Return on Equity (ttm)-1237.05%
Financial Strength
Current Ratio (mrq)0.22 
Debt/EquityN/A 
Total Cash (mrq)$544.0K
Short Interest
Shares ShortN/A 
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.